The study is a randomized, placebo-controlled, and double-blinded trial in patients with
aortic stenosis (AS) undergoing aortic valve replacement (AVR). After AVR, patients will be
randomized 1:1 to empagliflozin (SGLT2i) or placebo to investigate whether empagliflozin is
superior to placebo in reducing left ventricular mass and improve symptoms to 6 months.